期刊文献+

蛋白质药物长效化技术的现状和进展 被引量:9

Current Status and Progress on the Techniques for Prolonging Half-life of Protein Pharmaceuticals
原文传递
导出
摘要 综述了提高蛋白质药物半衰期技术的最新进展。由于蛋白质药物在体内会被快速清除,所以患者必须频繁用药才能保持药物浓度,限制了其治疗效果。因此,延长蛋白质药物体内的半衰期并阻止其被快速清除已成为近年来的研究热点。已建立的提高蛋白质药物半衰期的技术包括化学修饰、蛋白质融合、微囊化、糖基化、抗蛋白酶突变体等,许多长效蛋白质药物已经研制成功并应用于临床治疗。阐述了这些技术的原理并通过实例比较和评价了各种技术的优点和适用范围。 The latest developments of techniques that prolong the half-life of protein drugs were reviewed. The therapeutic potential of several proteins is limited by their rapid clearance from the body, resulting in the need for frequent treatment of individuals to maintain drug levels. Several techniques including chemical modification, protein fusion, microsphere, glycosylation, and protease-resistant variants, and so on, prevent rapid degradation of such drugs and prolong their half-lives in vivo. Several successful protein drugs with prolonged half-life have already been on the market or on clinical trials. The principles, efficiencies and scopes of application of these techniques were described, compared and discussed.s
作者 边蕾 石屹峰
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2009年第2期114-118,共5页 China Biotechnology
基金 辽宁省教育厅重点实验室资助项目(2008S015)
关键词 化学修饰 蛋白质融合 微囊化 糖基化 抗蛋白酶突变体 Chemical modification Protein fusion Microsphere Glycosylation Protease-resistant variant
  • 相关文献

参考文献19

  • 1王秀贞,吴军,孟宪军.长效多肽药物研究进展[J].中国生物工程杂志,2003,23(10):23-27. 被引量:6
  • 2Subramanian M G, Fiscella M, Lamouse-Smith A, et al. Albinterferoncα-2b :a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol, 2007,25 ( 12 ) : 1411 - 1419.
  • 3Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today, 2005, 10 (21) :1451 - 1458.
  • 4Stigsnaes P, Frokjaer S, Bjerregaard S, et al. Characterisation and physical stability of PEGylated glucagon. Int J Pharm, 2007, 330(1-2) :89 -98.
  • 5张兵,邹文艺,范清林,宋礼华.长效重组药物研究进展[J].生物学杂志,2008,25(3):9-12. 被引量:4
  • 6戚楠,马清钧.长效重组蛋白药物的研究进展[J].中国生物工程杂志,2006,26(2):79-82. 被引量:22
  • 7Duttaroy A, Kanakaraj P, Osborn L B, et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes, 2005, 54(1 ):251 -258.
  • 8Chen J Q, Bai G, Cao Y, et al. One-step purification of a fusion protein of glueagons-like peptide-1 and human serum albumin expressed in Pichia pastoris by an immunomagnetic separation technique. Biosei Biotechnol Biochem, 2007, 71 ( 11 ) :2655 - 2662.
  • 9Miiller D, Karle A, Meissburger B, et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem, 2007, 282 ( 17 ) : 12650 - 12660.
  • 10王磊,何剑,肖卫华.人干扰素α2b和IgGFc片段融合蛋白显著延长体内半衰期[J].生物工程学报,2008,24(1):53-62. 被引量:11

二级参考文献157

  • 1王萍,陈钧.酶抑制剂在蛋白质和肽类药物口服制剂中的应用[J].中国医药工业杂志,2005,36(8):510-514. 被引量:2
  • 2王宇新,周晓巍,党颖,黄培堂.提高蛋白质和多肽类药物代谢稳定性的研究进展[J].生物技术通讯,2005,16(6):665-667. 被引量:6
  • 3马清均主编.生物技术药物[M].北京:化学工业出版社,2002.50-51.
  • 4Elliott S, Egrie J, Browne J, et al. Control of rHuEPO biological activity: The role of carbohydrate. Experimental Hematology, 2004, 32 (12) :1146 - 1155.
  • 5Derek Macmillan. Selective in vitro glycosylation of recombinant proteins: semi-synthesis of novel homogeneous glycoforms of human erythropoietin. Chemistry & Biology, 2001,8 (2) :133- 145.
  • 6Sinclair A M, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci, 2005, 94 (8) :1626 - 1635.
  • 7Glaspy J. Phase Ⅲ clinical trials with darbepoetin: implications for clinicians. Best Pract Res Clin Haematol, 2005, 18 (3) :4O7 -416.
  • 8Dunn C J, Plosker G L, Keating G M, et al. Insulin glargine:an updated review of its use in the management of diabetes mellitus. Drugs, 2003, 63 (16) : 1743 -1778.
  • 9Scholtz H E, Pretorius S G, Wessels D H, et al.Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia,2005, 48(10) : 1988 - 1995.
  • 10Lee G K. PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol Bioeng,2005, 92( 1 ) :24 -34.

共引文献49

同被引文献97

引证文献9

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部